DENTSPLY (XRAY) analyst forecast and price target
Analyst forecast
Consensus of 19 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Market Perform | $10.00 from $14.00 | Oct 14, 2026 |
| Piper Sandler | Maintained | Neutral | $12.00 from $14.00 | Oct 9, 2026 |
| BMO Capital | Maintained | Market Perform | $10.00 from $13.00 | Sep 17, 2026 |
| Barclays | Maintained | Underweight | $11.00 from $9.00 | Aug 24, 2026 |
| Piper Sandler | Maintained | Neutral | $14.00 from $13.00 | Jul 29, 2026 |
| BMO Capital | Initiated Coverage | Market Perform | $12.00 | Jul 9, 2026 |
| Barclays | Maintained | Underweight | $9.00 from $12.00 | Jun 4, 2026 |
| UBS | Maintained | Buy | $17.00 from $18.00 | May 7, 2026 |
| Mizuho | Maintained | Neutral | $14.00 from $16.00 | May 6, 2026 |
| Citigroup | Initiated Coverage | Sell | $10.00 | Apr 15, 2026 |
| Barrington Research | Maintained | Outperform | $17.00 from $14.00 | Mar 2, 2026 |
| Mizuho | Maintained | Neutral | $16.00 from $14.00 | Mar 2, 2026 |
| Evercore ISI Group | Maintained | In-Line | $15.00 from $12.00 | Feb 27, 2026 |
| Baird | Maintained | Neutral | $14.00 from $12.00 | Feb 27, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $13.00 from $12.00 | Feb 27, 2026 |
| B of A Securities | Upgraded | Neutral → Buy | $17.00 from $13.00 | Feb 19, 2026 |
| UBS | Maintained | Buy | $16.00 from $17.00 | Feb 3, 2026 |
| Mizuho | Maintained | Neutral | $14.00 from $13.00 | Jan 20, 2026 |
| Barrington Research | Maintained | Outperform | $14.00 | Jan 5, 2026 |
| Baird | Maintained | Neutral | $12.00 from $14.00 | Dec 16, 2025 |
Frequently asked questions
What is the price target for XRAY stock?
The average 12-month analyst price target for DENTSPLY (XRAY) is $10.75, with a high estimate of $12.00 and a low of $10.00, across 4 analysts.
Is XRAY a buy, sell, or hold?
Analysts covering DENTSPLY currently average a Hold rating: 4 buy, 13 hold and 2 sell, from 19 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for XRAY?
The average price target of $10.75 implies 27.37% upside from the last price of $8.44.
What is the latest analyst rating on XRAY?
On Oct 14, 2026, Leerink Partners maintained DENTSPLY at Market Perform with a price target of $10.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.